MX2015011371A - Anticuerpos monoclonales anti-+)--metanfetamina. - Google Patents

Anticuerpos monoclonales anti-+)--metanfetamina.

Info

Publication number
MX2015011371A
MX2015011371A MX2015011371A MX2015011371A MX2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A
Authority
MX
Mexico
Prior art keywords
methamphetamine
monoclonal antibodies
subject
methamphetamine monoclonal
slowing
Prior art date
Application number
MX2015011371A
Other languages
English (en)
Inventor
Samuel Michael Owens
Ralph Henry
Alicia Brown
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Publication of MX2015011371A publication Critical patent/MX2015011371A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención abarca las composiciones y métodos para tratar con eficacia al menos un síntoma o señal de uso de la metanfetamina, o para disminuir la velocidad de entrada de (+) metanfetamina en el cerebro de un sujeto. El método comprende administrar una cantidad efectiva de un anticuerpo anti-(+) metanfetamina a un sujeto.
MX2015011371A 2013-03-13 2014-03-13 Anticuerpos monoclonales anti-+)--metanfetamina. MX2015011371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/802,688 US9023353B2 (en) 2013-03-13 2013-03-13 Anti-(+)—methamphetamine monoclonal antibodies
PCT/US2014/025890 WO2014160133A2 (en) 2013-03-13 2014-03-13 Anti-(+) --methamphetamine monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2015011371A true MX2015011371A (es) 2015-12-16

Family

ID=51527982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011371A MX2015011371A (es) 2013-03-13 2014-03-13 Anticuerpos monoclonales anti-+)--metanfetamina.

Country Status (11)

Country Link
US (1) US9023353B2 (es)
EP (1) EP2970503B1 (es)
JP (2) JP2016514153A (es)
AU (1) AU2014244120B2 (es)
BR (1) BR112015020718A2 (es)
CA (1) CA2901514C (es)
ES (1) ES2923643T3 (es)
HK (1) HK1215714A1 (es)
MX (1) MX2015011371A (es)
PL (1) PL2970503T3 (es)
WO (1) WO2014160133A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041076A (en) 1967-01-10 1991-08-20 Kantor Frederick W Rotary inertial thermodynamic multi-stage mass-flow divider
US4041076A (en) 1974-10-23 1977-08-09 Hoffmann-La Roche Inc. Immunoassay for pharmacologically active phenethylamines
US4329281A (en) 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
AU528246B2 (en) 1978-10-14 1983-04-21 Teikoku Hormone Mfg. Co., Ltd. Stable immunoassay reagent for hapten determination
DK159276C (da) 1980-03-31 1991-02-18 Takeda Chemical Industries Ltd Fremgangsmaade til isolering af specifikke antistoffer og enzym-immunbestemmelsesmetode med anvendelse af det isolerede antistof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5160701A (en) 1986-02-18 1992-11-03 Abbott Laboratories Solid-phase analytical device and method for using same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0737986B2 (ja) 1988-03-29 1995-04-26 松下電器産業株式会社 免疫的検出方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5135863A (en) 1988-12-23 1992-08-04 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
US5238652A (en) 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
CH678394A5 (es) 1990-08-22 1991-09-13 Cerny Erich H
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
CA2096495C (en) 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5492841A (en) 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5620890A (en) 1995-03-14 1997-04-15 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to hygromycin B and the method of making the same
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
IT1284076B1 (it) 1996-06-27 1998-05-08 Dox Al Italia Spa Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro
DE19630102A1 (de) 1996-07-25 1998-01-29 Boehringer Mannheim Gmbh Neue aktivierte Amphetamine
US6087184A (en) 1997-11-10 2000-07-11 Beckman Coulter, Inc. Opposable-element chromatographic assay device for detection of analytes
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
CA2395827A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7202348B2 (en) 2000-04-20 2007-04-10 The University Of Arkansas For Medical Sciences Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US6669937B2 (en) 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2001081424A1 (en) 2000-04-20 2001-11-01 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US20030171435A1 (en) 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
EP1331219A1 (en) 2002-01-23 2003-07-30 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
DE60335428D1 (de) 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
US20050013809A1 (en) 2002-12-02 2005-01-20 Owens Samuel M. Antibodies against drugs of abuse
US20040242848A1 (en) 2003-04-21 2004-12-02 Owens S. Michael Mouse/human chimeric anti-phencyclidine antibody and uses thereof
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7037669B2 (en) 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
WO2007147122A2 (en) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2140263B1 (en) * 2007-04-20 2017-01-04 The Board of Trustees of The University of Arkansas Hapten compounds and compositions and uses thereof
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도

Also Published As

Publication number Publication date
CA2901514A1 (en) 2014-10-02
EP2970503B1 (en) 2022-06-22
PL2970503T3 (pl) 2022-08-29
CA2901514C (en) 2021-02-16
AU2014244120B2 (en) 2018-07-19
US20140271686A1 (en) 2014-09-18
AU2014244120A1 (en) 2015-09-03
JP2019069957A (ja) 2019-05-09
EP2970503A2 (en) 2016-01-20
JP2016514153A (ja) 2016-05-19
ES2923643T3 (es) 2022-09-29
JP6560808B2 (ja) 2019-08-14
WO2014160133A2 (en) 2014-10-02
BR112015020718A2 (pt) 2017-10-10
US9023353B2 (en) 2015-05-05
HK1215714A1 (zh) 2016-09-09
EP2970503A4 (en) 2016-11-30
WO2014160133A3 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
TN2015000396A1 (en) Antibody drug conjugates
WO2016062722A8 (en) Combination
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
PH12017500864A1 (en) Anti-notch1 antibodies
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
EA201690446A1 (ru) Лечение множественной миеломы
CL2016000999A1 (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
MX2019014291A (es) Metodo de tratamiento.
MX2015011371A (es) Anticuerpos monoclonales anti-+)--metanfetamina.
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу